Actively Recruiting
Real-World Observational Study of Acalabrutinib for Chronic Lymphocytic Leukemia Treatment in Belarus Clinical Practice
Led by AstraZeneca · Updated on 2026-09-09
50
Participants Needed
4
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
This research aims to collect real-world data on the use of acalabrutinib for treating patients with chronic lymphocytic leukemia CLL in Belarus. The study focuses on understanding the treatments effectiveness, safety, and impact on patients quality of life in everyday clinical settings. It is an observational and prospective study without experimental interventions, where treatment decisions are made by patients clinicians. Participants will be observed while receiving acalabrutinib as prescribed in routine care. There is no control or comparison group involved. The study will follow each patient for about two years, with regular data collection intervals to monitor treatment progress and changes. All treatment choices and modifications remain under the clinicians discretion. During the study, participants will undergo periodic assessments to track treatment duration, any reasons for stopping or changing doses, treatment interruptions, and subsequent therapies used. Researchers will collect safety information and quality of life data over up to 25 months. This comprehensive monitoring helps provide essential insights into how acalabrutinib works in real clinical practice outside of controlled trials.
CONDITIONS
Brief Title
Observ Prosp Study of Acalabrutinib in CLL Therapy in Real Clinical Practice in Belarus
Research Team
A
AstraZeneca Clinical Study Information Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here